Elevance Health stock: Raised outlook keeps margin test in focus

Published on 11/06/2026 at 17:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elevance Health stock enters a new test after management raised its 2026 earnings outlook. Membership and margins remain key investor signals.

Outlook Raises The Next Test

Elevance Health lifted its 2026 adjusted earnings guidance after a stronger third quarter.
Medical membership declined year over year while Carelon delivered double-digit operating gain growth.
Management expects at least 12 percent adjusted earnings growth from its higher 2026 baseline in 2027.

Elevance Health, US0367521038, Illustration mit AI erstellt.

Elevance Health stock traded at 382.40 euros on Lang & Schwarz at 17:01 CET on Friday, November 6, 2026. The insurer is entering a new earnings phase after raising its 2026 outlook and setting a higher baseline for 2027 growth.

In its October 21 earnings release, Elevance Health reported third-quarter operating revenue of 50.4 billion US dollars, up 0.7 percent from the prior-year quarter. Adjusted diluted earnings reached 6.99 US dollars per share, while the benefit expense ratio improved by 70 basis points to 90.6 percent.

Higher Guidance, Mixed Membership

Management raised full-year 2026 adjusted diluted earnings guidance to at least 29 US dollars per share and operating cash flow guidance to at least 6.5 billion US dollars. The company also lifted its underlying 2026 earnings baseline to at least 26.75 US dollars and said it expects at least 12 percent adjusted earnings growth in 2027 from that baseline.

The operating picture remains uneven. Medical membership stood at approximately 44.9 million at September 30, down 487,000 from a year earlier as Medicaid, Medicare Advantage and employer risk-based enrollment declined. Carelon operating revenue rose 5 percent to 19.3 billion US dollars, while operating gain increased 17 percent to 0.9 billion US dollars.

What Changed Since The Last Report

The latest quote provides a fresh comparison with the most recent relevant report on October 27, when the stock was cited at 377.80 euros. The current 382.40-euro quote is 1.22 percent above that level, giving investors a new market reference while the operating debate shifts toward Medicaid margins, membership and the durability of the raised outlook.

Investors can follow the real-time quote of Elevance Health stock as the next company update approaches.

The broader US market backdrop remains relevant for insurers and other defensive equities; see the latest S&P 500 market coverage.

For further sector developments, see more news and analyses on Elevance Health stock.